Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Table 3 First line treatment

Variable	Overall cohort		RVd (six 21-day cycles)		isatuximab-RVd (six 21-day cycles)		RVd (four 21-day cycles)		elotuzumab-RVd (four 21-day cycles)		p value
Variable	n	%	n	%	n	%	n	%	n	%	p value
Patient number	179	100	44	100	35	100	51	100	49	100	/
Remission post induction											0.006^a
CR and nCR	52	29	22	50	12	34	10	20	8	16
VGPR	76	42	10	23	16	46	25	49	25	51
PR or worse	51	29	12	27	7	20	16	32	16	33
Median number of induction cycles (range)	4	(4–6)	6	(4–6)	6	(4–6)	4	(3–4)	4	(3–4)	/

^aCR + nCR versus VGPR versus PR or worse
ABSCT Autologous blood stem cell transplantation, CR Complete response, HDCT High-dose chemotherapy, MR Minimal response, NA Not available, n.a. Not applicable, nCR Near complete response, PBSC Peripheral blood stem cells, PD Progressive disease, PR Partial response, RVd Lenalidomide, bortezomib, dexamethasone, SD Stable disease, VGPR Very good partial response, VCD Bortezomib, cyclophosphamide, dexamethasone

ISSN: 1471-2407